Inozyme Pharma Stock Equity Positions Weight
INZY Stock | USD 1.36 0.02 1.45% |
Inozyme Pharma fundamentals help investors to digest information that contributes to Inozyme Pharma's financial success or failures. It also enables traders to predict the movement of Inozyme Stock. The fundamental analysis module provides a way to measure Inozyme Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inozyme Pharma stock.
Inozyme | Equity Positions Weight |
Inozyme Pharma Company Equity Positions Weight Analysis
Inozyme Pharma's Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.
More About Equity Positions Weight | All Equity Analysis
Stock Percentage | = | % of Equities | in the fund |
Inozyme Equity Positions Weight Driver Correlations
Understanding the fundamental principles of building solid financial models for Inozyme Pharma is extremely important. It helps to project a fair market value of Inozyme Stock properly, considering its historical fundamentals such as Equity Positions Weight. Since Inozyme Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inozyme Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inozyme Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.
Competition |
According to the company disclosure, Inozyme Pharma has an Equity Positions Weight of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Inozyme Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inozyme Pharma from analyzing Inozyme Pharma's financial statements. These drivers represent accounts that assess Inozyme Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inozyme Pharma's important valuation drivers and their relationship over time.
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Market Cap | 482.7M | 160.7M | 39.7M | 220.8M | 254.0M | 263.1M | |
Enterprise Value | 324.1M | 140.7M | 13.5M | 232.8M | 267.8M | 215.4M |
Inozyme Fundamentals
Return On Equity | -0.79 | ||||
Return On Asset | -0.36 | ||||
Current Valuation | 2.55 M | ||||
Shares Outstanding | 64.24 M | ||||
Shares Owned By Insiders | 0.50 % | ||||
Shares Owned By Institutions | 98.58 % | ||||
Number Of Shares Shorted | 3.7 M | ||||
Price To Book | 1.06 X | ||||
EBITDA | (74.81 M) | ||||
Net Income | (71.17 M) | ||||
Cash And Equivalents | 151.48 M | ||||
Cash Per Share | 3.77 X | ||||
Total Debt | 46.59 M | ||||
Debt To Equity | 0.02 % | ||||
Current Ratio | 14.54 X | ||||
Book Value Per Share | 1.29 X | ||||
Cash Flow From Operations | (70.67 M) | ||||
Short Ratio | 4.69 X | ||||
Earnings Per Share | (1.55) X | ||||
Price To Earnings To Growth | (0.06) X | ||||
Target Price | 18.0 | ||||
Number Of Employees | 59 | ||||
Beta | 1.54 | ||||
Market Capitalization | 87.37 M | ||||
Total Asset | 200.85 M | ||||
Retained Earnings | (285.93 M) | ||||
Working Capital | 181.56 M | ||||
Net Asset | 200.85 M |
About Inozyme Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inozyme Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inozyme Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inozyme Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.BTC | Bitcoin | |
TRX | TRON | |
BNB | Binance Coin |
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.